WEHRWEIN SVEN sold $946K of ATRC
WEHRWEIN SVEN sold 25,000 shares of AtriCure, Inc. (ATRC) at $37.84 ($0.95M total) on 2026-07-28.
How this was made
The 30-second read
Why it matters
The disclosed open-market sale may slightly affect sentiment, but it does not provide new guidance, trial results, contracts, or regulatory developments.
Market read
Traders may monitor insider activity as a sentiment input, but this filing alone is unlikely to change the fundamental outlook.
What to watch
The filing states no pre-arranged 10b5-1 plan, but the article provides no context on motivations or whether other insiders sold/bought around the same time.
Background
The article is an SEC Form 4 insider transaction disclosure for AtriCure, Inc.
Ticker impact
AtriCure director WEHRWEIN SVEN filed a Form 4 open-market sale of 25,000 shares at $37.84 on 2026-07-28.
Low likelihood of a sustained price move solely from this sale; any impact is likely short-lived and sentiment-driven.
This is a routine insider transaction disclosure with no 10b5-1 plan and no accompanying operational or financial update in the text.
Market effects
No sector-wide implications are stated; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs, so the signal may be weak.
Key entities
- issuerAtriCure, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderWEHRWEIN SVEN
Director who sold 25,000 shares in an open-market transaction.
